| Adriamycin plus bleomycin versus cyclophosphamide plus vincristine in advanced carcinoma of the uterine cervix. | |
| | |
MedLine Citation:
|
PMID: 65039 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The paper reports the results of a prospective controlled study with two drug combinations (adriamycin plus bleomycin versus cyclophosphamide plus vincristine) in 34 consecutive patients with advanced or recurrent carcinoma of uterine cervix. Despite adequate dosage, the incidence of complete and partial remission was low (10% vs 20%) and not superior to that usually obtained with single agent chemotherapy. By adding objective improvement, the over all response rate was 47% and 26%, respectively. The duration of complete plus partial remission was 7.5 and 7.2 months, the median survival for responders 19 and 8.3 months, respectively. After cross over, adriamycin plus bleomycin yielded response in 4/10 patients, cyclophosphamide plus vincristine objective improvement in 1/3 patients. Since the control of advanced cervical carcinoma remains difficult, a combined modality approach with radiotherapy plus adjuvant chemotherapy for stages IIB and III appears worth of trial. |
| | |
Authors:
|
G M Palo; E Bajetta; G Beretta; G Bonadonna |
Related Documents
:
|
21724429 - Clinicopathologic analysis of the impact of cd23 expression in plasma cell myeloma with... 21930979 - Human papillomavirus type 16 oropharyngeal cancers in lymph nodes as a marker of metast... 975039 - Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the bre... 6668489 - Analysis of survival by tumor response. 177209 - Vincristine (nsc-67574) in the treatment of small-cell anaplastic carcinoma of the lung. 21898089 - Human equilibrative nucleoside transporter 1 expression is a strong independent prognos... 19330839 - P16ink4a expression in cytology of ascites and response to chemotherapy in advanced ova... 22414279 - Normal tissue complication probability modeling of acute hematologic toxicity in patien... 21724429 - Clinicopathologic analysis of the impact of cd23 expression in plasma cell myeloma with... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Tumori Volume: 62 ISSN: 0300-8916 ISO Abbreviation: Tumori Publication Date: 1976 Jan-Feb |
Date Detail:
|
Created Date: 1977-03-21 Completed Date: 1977-03-21 Revised Date: 2008-12-12 |
Medline Journal Info:
|
Nlm Unique ID: 0111356 Medline TA: Tumori Country: ITALY |
Other Details:
|
Languages: eng Pagination: 113-22 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Bleomycin / therapeutic use* Cyclophosphamide / therapeutic use* Doxorubicin / therapeutic use* Drug Therapy, Combination Female Humans Middle Aged Remission, Spontaneous Uterine Cervical Neoplasms / drug therapy* Vincristine / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
11056-06-7/Bleomycin; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 57-22-7/Vincristine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effect of timing of skin grafts on subsequent survival in ALS-treated, marrow-infused mice.
Next Document: Therapy of advanced esophageal cancer with bleomycin, irradiation and combination of bleomycin with ...